Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Background: So far only trastuzumab, pembrolizumab and ramucirumab have been approved by the FDA for targeted therapy in gastric cancer (GC). Here we report on potential targeted therapy options for gastric adenocarcinoma based on a novel analysis of “The Cancer Genome Atlas (TCGA)” database. Methods: One hundred two FDA-approved targeted cancer drugs were compiled and molecular targets defined. Drugs were considered as potentially effective if targeted genes showed (1) an increase in copy number, (2) gain of function with oncogene activation, (3) specific alterations responsive to approved drugs. Additionally, genetic changes that confer drug resistance and/or sensitivity were evaluated. Results: Fifty percentage of patients with GC may be treatable with non-GC but FDA-approved targeted cancer therapies. The major drug identified in our in silico study for GC is copanlisib, a PI3K inhibitor. In the TCGA patient database, our genetically based drug response prediction identified more patients with alterations sensitive to copanlisib compared to the already-GC-approved drug trastuzumab (20%, 78 out of 393 patients, vs. trastuzumab: 13%, 52 of 393 patients), which is mainly due to the high incidence of PIK3CA gain of function mutations within mutation hot spots. Conclusion: Our results demonstrate that various currently FDA-approved drugs might be candidates for targeted therapy of GC. For clinical trials, cancer patients should be selected based on the genomic profile of their tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Flowchart of data processing: shown are the major steps of data analysis based on the computational query of drugs for targeted therapy on the respective patient’s data with gastric cancer (GC). Further analysis took into consideration gene amplification and gain of function as well as known alterations of genes to reach a conclusion on target options for GC. Abbreviations: FDA Food and Drug Administration; TCGA The Cancer Genome Atlas [9]; CNV Copy Number Variants based on GISTIC 2.0 algorithm [20]; MAF Mutation Annotation Format based on MutSig 2CV algorithm [19]; RPPA reverse phase protein array based on Z-score (overexpression z ≥ 2, underexpression z ≤ − 2) [18]; gene fusion data were taken out of the supplementary of the STAD-TCGA publication [22]; STAD stomach adenocarcinoma; CiViC Clinical Interpretation of Variance in Cancer database [14]; MyCancerGenome database [11]; DoCM Database of Curated Mutations database [46]; OncoKB Precision Oncology Base databases (drugs actionable variance, all variance with biological effects [16]); PCT MD Anderson Center for Personalized Cancer Therapy [13]; COSMIC Catalogue of Somatic Mutations in Cancer database on drug resistance [47].](https://figures.cochat.ai/paper-figures/8c0a6b1786e74d6dabbcdb7c692b369a/identification-of-targeted-therapy-options-for-gastric-adenocarcinoma-by-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A major GC target identified in this analysis was the high frequency of PIK3CA mutation variants.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [70]
The cited source says what the claim attributes to it.
In the citing paper
“Other drugs identified here for therapeutic options are sorafenib (16% of TCGA GC patients), cobozantinib, and regorafenib [70].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [70]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, 50% of the patients would be predicted to benefit from FDA-approved alternative targeted therapies.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [70]
The cited source says what the claim attributes to it.
In the citing paper
“Based on in silico data mining, the treatment benefit of up to 15% of GC samples from the TCGA dataset can be predicted by currently approved targeted therapy for GC (trastuzumab, pembrolizumab, and ramucirumab).”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [70]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
COSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Chang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808
Griffith, M., Spies, N. C., Krysiak, K., McMichael, J. F., Coffman, A. C., Danos, A. M., Ainscough, B. J., Ramirez, C. A., Rieke, D. T., Kujan, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3774 · Cited by 628
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Rodon, J., Soria, J.-C., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0424-4 · Cited by 578
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Schwaederle, M., Zhao, M., Lee, J. J., Eggermont, A. M., Schilsky, R. L., Mendelsohn, J., Lazar, V., & Kurzrock, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5997 · Cited by 494
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen, M. H., Williams, G., Johnson, J. R., Duan, J. Z., Gobburu, J. V. S., Rahman, A., Benson, K. A., Leighton, J. K., Kim, S. K., Wood, R., et al. (2002) · PubMed · Cited by 462
for the SAKK and the German CML Study Group, Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.253 · Cited by 341
Bang, Y.-J., Kang, Y.-K., Catenacci, D. V., Muro, K., Fuchs, C. S., Geva, R., Hara, H., Golan, T., Garrido, M., Jalal, S. I., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-018-00909-5 · Cited by 245
Pavlakis, N., Sjoquist, K. M., Martin, A. J., Tsobanis, E., Yip, S., Kang, Y.-K., Bang, Y.-J., Alcindor, T., O’Callaghan, C. J., Burnell, M. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1901 · Cited by 232
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Massacesi, C., Di Tomaso, E., Urban, P., Germa, C., Quadt, C., Trandafir, L., Aimone, P., Fretault, N., Dharan, B., Tavorath, R., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s89967 · Cited by 229
Lee, J., Kim, S. T., Kim, K., Lee, H., Kozarewa, I., Mortimer, P. G. S., Odegaard, J. I., Harrington, E. A., Lee, J., Lee, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0442 · Cited by 228
Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell
Gao, J.-P., Xu, W., Liu, W.-T., Yan, M., & Zhu, Z.-G. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i24.2567 · Cited by 181
Yamashita-Kashima, Y., Iijima, S., Yorozu, K., Furugaki, K., Kurasawa, M., Ohta, M., & Fujimoto-Ouchi, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2927 · Cited by 176
Hao, H.-X., Jiang, X., & Cong, F. (2016) · Cancers · doi:10.3390/cancers8060054 · Cited by 171
Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications
Gullo, I., Carneiro, F., Oliveíra, C., & Almeida, G. M. (2017) · Pathobiology · doi:10.1159/000473881 · Cited by 166
Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
Lee, H. E., Park, K. U., Yoo, S. B., Nam, S. K., Park, D. J., Kim, H.-H., & Lee, H. S. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.018 · Cited by 161
Tonra, J. R., Deevi, D. S., Corcoran, E., Li, H., Wang, S., Carrick, F. E., & Hicklin, D. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1682 · Cited by 148
DoCM: a database of curated mutations in cancer
Ainscough, B. J., Griffith, M., Coffman, A. C., Wagner, A. H., Kunisaki, J., Choudhary, M. N., McMichael, J. F., Fulton, R. S., Wilson, R. K., Griffith, O. L., et al. (2016) · Nature Methods · doi:10.1038/nmeth.4000 · Cited by 116
Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC
Maione, P., Gridelli, C., Troiani, T., & Ciardiello, F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-274 · Cited by 103
Martín-Richard, M., Gallego, R., Pericay, C., García‐Foncillas, J., Queralt, B., Casado, E., Barriuso, J., Iranzo, V., Juez, I., Visa, L., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0020-2 · Cited by 80
Analysis-ready standardized TCGA data from Broad GDAC Firehose 2016_01_28 run
Broad Institute TCGA Genome Data Analysis Center (2016) · The Broad Institute - Data Science Platform · doi:10.7908/c11g0km9 · Cited by 73
Reverse phase protein arrays in signaling pathways: a data integration perspective
Huang, S., & Creighton, C. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s38375 · Cited by 67
Wu, S.-G., Chang, Y.-L., Yu, C.-J., Yang, P.-C., & Shih, J.-Y. (2016) · Scientific Reports · doi:10.1038/srep35249 · Cited by 65
Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma
Kang, N., Wang, Y., Guo, S., Ou, Y., Wang, G., Chen, J., Li, D., & Zhan, Q. (2018) · BMC Cell Biology · doi:10.1186/s12860-018-0167-y · Cited by 31
Eltantawy, A., Vallejos, X., Sebea, E., & Evans, K. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019833992 · Cited by 27
Nishida, T., Casali, P. G., Reichardt, P., Kang, Y., Blay, J., Joensuu, H., Maki, R. G., Rutkowski, P. L., Hohenberger, P., Gelderblom, H. A. J., et al. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)31970-0 · Cited by 22
Demetri, G. D., Reichardt, P., Kang, Y., Blay, J., Joensuu, H., Maki, R. G., Rutkowski, P. L., Hohenberger, P., Gelderblom, H. A. J., Leahy, M. G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.lba10008 · Cited by 18
Cited by
Matsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“Other drugs identified here for therapeutic options are sorafenib (16% of TCGA GC patients), cobozantinib, and regorafenib [70].”
BackgroundTargeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis
Hescheler, D. A., Riemann, B., Hartmann, M. J. M., Michel, M., Faust, M., Bruns, C. J., Alakus, H., & Chiapponi, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.748941 · Cited by 18
Self-citationIdentification of Key Genes as Potential Drug Targets for Gastric Cancer
Hossain, M. T., Reza, M. S., Peng, Y., Feng, S., & Wei, Y. (2023) · Tsinghua Science & Technology · doi:10.26599/tst.2022.9010035 · Cited by 15
Zhang, L., Pan, J., Wang, Z., Yang, C., Chen, W., Jiang, J., Zheng, Z., Jia, F., Zhang, Y., Jiang, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.788778 · Cited by 13
Hescheler, D. A., Hartmann, M. J. M., Riemann, B., Michel, M., Bruns, C. J., Alakus, H., & Chiapponi, C. (2022) · Cancers · doi:10.3390/cancers14112721 · Cited by 12
Self-citation
Metadata
- Authors
- Hescheler, D. A., Plum, P. S., Zander, T., Quaas, A., Korenkov, M., Gassa, A., Michel, M., Bruns, C. J., & Alakus, H.
- Affiliations
- University Hospital Cologne (DE)
- University of Cologne (DE)
- Corresponding author
- Alakus, Hakan
- ORCID
- Venue
- Gastric Cancer
- Published
- 2020-02-27
- Volume
- 23
- Issue
- 4
- Pages
- 627-638
- ISSN
- 1436-3291 (ISSN-L)
- 1436-3305
- PMC
- PMC7305081
- OpenAlex
- W3007137621
- Cited by
- 12
- References
- 41
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 1 · 2020: 1
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Gastric Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- gastric adenocarcinoma, targeted therapy, drug repurposing, copanlisib, PI3K inhibitors, PIK3CA mutation, oncogene activation, copy number alterations, drug resistance, drug response prediction, trastuzumab, patient selection for clinical trials
- MeSH terms
- Adenocarcinoma, Antineoplastic Agents, Humans, Prognosis, Stomach Neoplasms, Biomarkers, Tumor, Genome, Human, Drug Resistance, Neoplasm, Genomics, Molecular Targeted Therapy, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.